Rituximab therapy for recurrent thromboembolic disease in antiphospholipid syndrome

Abstract

Get full access to this article

View all access options for this article.

References

Hughes

. The antiphospholipid syndrome: Ten years on. Lancet 1993; 342: 341–344.

Fonseca

D’Cruz

. Controversies in the antiphospholipid syndrome: Can we ever stop warfarin? J Autoimmune Dis 2008; 5: 6–6.

Martinuzzo

Forastiero

. Prothrombotic mechanisms based on the impairment of fibrinolysis in the antiphospholipid syndrome. Lupus 2008; 17: 872–872.

Veneri

Ambrosetti

Franchini

. Remission of severe anti-phospholipid syndrome associated with non-Hodgkin B cell lymphoma after combined treatment with Rituximab and chemotherapy. Haematologica 2005; 90: 16–17.

Trappe

Loew

Thuss-Patience

. Successful treatment of thrombocytopenia in Primary APS with anti-CD20 antibody Rituximab-monitoring on antiphospholipid and anti-GP antibodies: A case report. Ann Hematol 2006; 85: 134–135.

Rubenstein

Arkfeld

Metyas

. Rituximab treatment for resistant antiphospholipid syndrome. J Rheumatol 2006; 33: 355–357.

Weide

Heymanns

Pandorf

. Successful long term treatment of systemic lupus erythematosus with rituximab maintenance therapy. Lupus 2003; 12: 779–782.

Erre

Pardini

Faedda

. Effect of rituximab on clinical and laboratory features of antiphospholipid syndrome: A case report and a review of literature. Lupus 2008; 1: 50–55.

Manz

Arce

Cassese

. Humoral immunity and long lived plasma cells. Curr Opinion Immunol 2002; 14: 517–521.

10.

Eekan

Vega

Ramon

. A pilot open-label phase 11 trial of rituximab for non-criteria manifestations of antiphospholipid syndrome. Arthritis Rheum 2013; 65: 464–471.